Three-week hepatitis B vaccination provides protective immunity.

Abstract

To determine whether a 3-week hepatitis B (HB) vaccination could achieve protective immunity, 89 healthy non-immunized young adults received three doses of 20 micrograms each of HBs antigen (GenHevac B, Pasteur) and were randomly assigned to schedule A (n = 44): two doses at day 0, one dose at day 21; or schedule B (n = 45): one dose at days 0, 10 and 21. Seroprotection rates (anti-HBs > or = 10 mIU ml-1) for groups A and B respectively were: 23 and 40% at day 21; and 77 and 91% at day 82 (not significant). Anti-HBs geometric mean titres were higher in group B than in group A (p < 0.05) at days 21 (6.4 versus 3.8) and 82 (77.6 versus 33.5). One year after primary vaccination, the seroprotection rate remained as high as 90% in the vaccinees of group B; after boosting all vaccinees had protective levels of anti-HBs antibodies. Thus 3-week HB vaccination with GenHevac B allowed early and durable protective immunity.

• Authors: B Marchou, N Picot, P Chavanet, J C Auvergnat, M Armengaud, P Devilliers, J E Cerisier, F N Marié, J L Excler
• Journal: Vaccine (Vaccine) Vol. 11 Issue 14 Pg. 1383-5 (Nov 1993) ISSN: 0264-410X [Print] Netherlands
• PMID: 8310757 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Hepatitis B Antibodies
• Hepatitis B Vaccines

Topics

• Adolescent
• Adult
• Drug Administration Schedule
• Female
• Hepatitis B (immunology, prevention & control)
• Hepatitis B Antibodies (blood)
• Hepatitis B Vaccines (administration & dosage, immunology, therapeutic use)
• Humans
• Male
• Vaccination